Medical Condition News

RSS

Study examines effects of AEDs on nicotine metabolite levels in smokers

UMDNJ-Robert Wood Johnson Medical School researchers have determined that carbamazepine and oxycarbamazepine, medications commonly used to treat neurologic and psychiatric conditions, increase nicotine metabolism in smokers. As nicotine metabolism increases, cravings for nicotine return more quickly which could lead to more frequent cigarette consumption among individuals who also take these medications.

18 Sep 2010

Pazopanib drug reduces thyroid cancer progression: Study

The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.

18 Sep 2010

POWER study: Women with diabetes have C-section, complications during pregnancy

Nearly half of women with diabetes prior to pregnancy have a potentially-avoidable C-section and their babies are twice as likely to die as those born to women without diabetes, according to the POWER study.

18 Sep 2010

APC gene mutation affects DNA methylation in colon cancer: Research

Colon cancer is the second most common cancer in the United States and causes more than 50,000 deaths each year. It has been known for some time that mutations in the APC gene occur in more than 85 percent of all sporadic colon cancers. Now researchers at Huntsman Cancer Institute at the University of Utah demonstrate in a study featured today in Cell the mechanism by which mutation of the APC gene affects a cellular process known as DNA methylation.

18 Sep 2010

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Detailed cholesterol testing for Type 2 diabetes patients is the focus of a newly published article by Atherotech Diagnostics Lab Chief Medical Officer Michael E. Cobble, M.D. The article discusses the clinical advantages of advanced cholesterol testing in reducing cardiovascular disease (CVD) risk in patients with Type 2 diabetes and details several currently available advanced lipid tests, including the VAP® Cholesterol Test from Atherotech.

18 Sep 2010

LCA receives Leadership in Advocacy Award

Lung Cancer Alliance received the Leadership in Advocacy Award at today's forum of the Congressional Black Caucus Health Braintrust in Washington D.C.

18 Sep 2010

Minocycline plus N-acetylcysteine may help treat TBI

Traumatic brain injury (TBI) is a serious public health problem in the United States. Recent data show that approximately 1.7 million people sustain a traumatic brain injury annually. While the majority of TBIs are concussions or other mild forms, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability.

18 Sep 2010

Use of oral medications for diabetes increases among Americans: Report

The proportion of Americans reporting treatment for diabetes who took oral medications to treat their condition increased from 60 percent in 1997 to 77 percent in 2007, a 28 percent increase according to the latest News and Numbers from the Agency for Healthcare Research and Quality. During the same period, the proportion taking insulin to control their diabetes fell from 38 percent to 24 percent.

18 Sep 2010

Researchers identify new target for cystic fibrosis

The lab of Kevin Foskett, PhD, the Isaac Ott Professor of Physiology at the University of Pennsylvania School of Medicine, has found a possible new target for fighting cystic fibrosis (CF) that could compensate for the lack of a functioning ion channel in affected CF-related cells. Their finding appears in the Journal of Clinical Investigation.

18 Sep 2010

FDA accepts to review Aricept NDA for Alzheimer's disease

Teikoku Pharma USA, Inc., an international specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new weekly transdermal patch of Aricept, a leading medication for the treatment of Alzheimer's disease.

18 Sep 2010

FDA reviews Actos drug for bladder cancer risk

The U.S. Food and Drug Administration today announced it has begun a safety review of the diabetes drug Actos (pioglitazone), after receiving preliminary results from a long-term observational study designed to evaluate the risk of bladder cancer associated with use of this drug.

18 Sep 2010

Elixir Medical commences enrollment in EXCELLA BD trial for DESyne BD Novolimus Eluting CSS

Elixir Medical Corporation, a developer of product platforms that combine innovative medical devices with potent pharmaceuticals for site-specific therapies, announced the initiation of patient enrollment in the EXCELLA BD Randomized Clinical Trial designed to evaluate Elixir's next generation Novolimus Eluting Coronary Stent System (CSS) with bioabsorbable coating, the Elixir DESyne BD Novolimus Eluting CSS.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Accuray Incorporated showcases CyberKnife VSI System at ESTRO Annual Congress

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29, the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain.

18 Sep 2010

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

$Study on role of SurgiCase Orthopaedics in correction of compound wrist fractures$

Study on role of SurgiCase Orthopaedics in correction of compound wrist fractures

Materialise announced that it would lend its considerable expertise in virtual surgical planning to researcher Dr. J. B. Jupiter, Chief Hand and Upper Extremity Service at Massachusetts General Hospital. Through an AO funded, IRB approved study, Dr. Jupiter will use SurgiCase(R) Orthopaedics to explore the advantages of computer-assisted surgery, virtual 3D planning and intra-operative use of patient-specific surgical guides in osteotomies to correct compound wrist fractures-the first research project of its kind.

17 Sep 2010

DaVita launches Kidney Awareness Run|Walks for chronic kidney disease

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), today announced its launch of the 5th annual DaVita Kidney Awareness Run|Walks, a 10 city series of 5K events raising funds and awareness of CKD across the nation.

17 Sep 2010

Inspire Pharmaceuticals to present denufosol tetrasodium therapy data at ERS Annual Congress

Inspire Pharmaceuticals, Inc. announced today that data will be presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during oral and poster presentations at the European Respiratory Society (ERS) Annual Congress September 18 - 22, 2010 in Barcelona, Spain.

17 Sep 2010

Transition stops TT-223 gastrin analogue combination clinical study in type 2 diabetes

Transition Therapeutics Inc. announced today that a clinical study of gastrin analogue TT-223 in combination with a Lilly proprietary GLP-1 analogue in patients with type 2 diabetes did not meet its efficacy endpoints. Given these findings, there will be no further development of TT-223.

17 Sep 2010

CID to provide update on Cre8 polymer-free DES program at TCT 2010

CID s.r.l., a European company leader in interventional medicine, will update interventional cardiologists on the status of their revolutionary drug eluting stent technology during The Drug Eluting Stent (DES) Summit at TCT 2010, Washington, DC on Wednesday, September 22, 2010. The lecture, entitled "Status of the CID Cre8 polymer-free DES program", will be delivered by Alexandre Abizaid, MD, PhD. Chief of Intervention at Instituto Dante Pazzanese, in Sao Paulo Brazil, and will be part of the session "The Next Generation DES, Polymer-Free".

17 Sep 2010